0 CHECKOUT

West Nile Virus Infections - Pipeline Review, H1 2015

  • ID: 3266292
  • April 2015
  • 55 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • BioDiem Ltd
  • CEL-SCI Corporation
  • GlaxoSmithKline plc
  • Kineta, Inc.
  • MORE

West Nile Virus Infections - Pipeline Review, H1 2015

Summary

This, ‘West Nile Virus Infections - Pipeline Review, H1 2015’, provides an overview of the West Nile Virus Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for West Nile Virus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for West Nile Virus Infections and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • BioDiem Ltd
  • CEL-SCI Corporation
  • GlaxoSmithKline plc
  • Kineta, Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
West Nile Virus Infections Overview
Therapeutics Development
Pipeline Products for West Nile Virus Infections - Overview
Pipeline Products for West Nile Virus Infections - Comparative Analysis
West Nile Virus Infections - Therapeutics under Development by Companies
West Nile Virus Infections - Therapeutics under Investigation by Universities/Institutes
West Nile Virus Infections - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
West Nile Virus Infections - Products under Development by Companies
West Nile Virus Infections - Products under Investigation by Universities/Institutes
West Nile Virus Infections - Companies Involved in Therapeutics Development
BioDiem Ltd
CalAsia Pharmaceuticals, Inc.
CEL-SCI Corporation
GlaxoSmithKline plc
Kineta, Inc.
West Nile Virus Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BG-323 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EMER-IT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ETX-112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HydroVax-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Innate Immune Adjuvants - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Innate Immune Agonists - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for West Nile Virus Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for West Nile Virus Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rOAS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit NS2B-NS3 Protease for Dengue and West Nile Virus Infection - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit NS5 for Dengue and Flavivirus Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for West Nile Virus Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Serine Protease for Viral Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides for West Nile Virus and Dengue Virus Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
west nile vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
west nile virus vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
west nile virus vaccine 2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
West Nile Virus Infections - Recent Pipeline Updates
West Nile Virus Infections - Dormant Projects
West Nile Virus Infections - Product Development Milestones
Featured News & Press Releases
Apr 20, 2010: Kineta Scientist to Present Novel Antiviral Research Findings at International Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for West Nile Virus Infections, H1 2015
Number of Products under Development for West Nile Virus Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
West Nile Virus Infections - Pipeline by BioDiem Ltd, H1 2015
West Nile Virus Infections - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2015
West Nile Virus Infections - Pipeline by CEL-SCI Corporation, H1 2015
West Nile Virus Infections - Pipeline by GlaxoSmithKline plc, H1 2015
West Nile Virus Infections - Pipeline by Kineta, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
West Nile Virus Infections Therapeutics - Recent Pipeline Updates, H1 2015
West Nile Virus Infections - Dormant Projects, H1 2015
West Nile Virus Infections - Dormant Projects (Contd..1), H1 2015

List of Figures
Number of Products under Development for West Nile Virus Infections, H1 2015
Number of Products under Development for West Nile Virus Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

BioDiem Ltd
CalAsia Pharmaceuticals, Inc.
CEL-SCI Corporation
GlaxoSmithKline plc
Kineta, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.